Enabling the development of high-quality evidence to transform research and care.

NeuroBlu is a data analytics platform built by Holmusk that is powered by the world’s leading source for real-world data on behavioral health conditions, symptoms, and treatments. With NeuroBlu, find the answers to address challenging behavioral health questions—faster and easier than ever before

Holmusk is a global digital health and data analytics company, focused on solving complex problems in healthcare for chronic diseases. It builds innovative, scalable and cost-effective digital behaviour change programs that combine cutting-edge clinical research, technology and design to nudge people towards sustainable changes for better health. It develops powerful predictive algorithms that offer actionable insights for personalised care and population health management. Holmusk was founded in 2015 and is based in Singapore, Malaysia and USA.

Real recovery requires support from healthcare providers, family members, and peers. Unfortunately, relapse risk after treatment is high – the relapse rate is estimated between 40 – 60%. CHESS Health provides evidence-based support programs that function as a safety net for individuals in recovery – particularly during the hours, days, and weeks that stressors and risks are most likely to surface – and when individuals are not in front of their healthcare treatment provider. The CHESS Connections app, which supports individuals in building healthy habits, reducing isolation, and celebrating achievements, is the foundation of a robust virtual community. CHESS Health’s certified peer recovery specialists, who have lived experience in SUD, moderate lively discussion groups and host video support meetings, creating meaningful engagement and dialogue around the issues that matter most – and support individuals 24/7. The platform even includes digital behavior change programs, allowing individuals to access bite-sized training on an as-needed basis.

CHESS Health creates innovative solutions designed at the intersection of science, technology, and recovery. Founded in 2014 by nationally recognized substance abuse researcher Dr. Dave Gustafson, CHESS developed A-CHESS- the leading evidence-based relapse prevention technology. By integrating A-CHESS into treatment plans, clinicians, case managers and coaches can best support those in recovery with access to predictive relapse analytics, condition-specific content and access to live support, reducing relapse by 50 percent while decreasing costs and saving lives. A leader in the mHealth space, the A-CHESS platform received recognition from the Substance Abuse and Mental Health Services Administration’s National Registry of Evidence-based Programs and Practices (NREPP), the Journal of Substance Abuse and the Surgeon General.

Designed by a team of data scientists, clinicians, and industry experts, NeuroBlu's robust tools drive real-world evidence generation with unparalleled ease.

NeuroBlu's custom-built architecture brings the power of high-performance computing and innovation to real-world studies. User-friendly tools streamline typically laborious and error-prone steps in analysis, enabling users to get to insights without having to spend hours cleaning data and troubleshooting code. Built-in custom libraries let you use the data with ease - no need to spend hours navigating a complex data model, because our data scientists did it for you.

Our eRecovery solution, encompassing our evidence-based Connections App, provides individuals with 24/7 support to sustain and strengthen their recovery between outpatient visits. Clinical trials and customer implementations have found that individuals with the app were more likely to make their next appointment and stay in treatment. Their long-term outcomes are better too; health plans and others have measured lower rates of return to a higher level of care (detox, residential, inpatient) among those with the support of the app.